Natera, Inc.(NTRA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NTRA Natera, Inc.

未开盘 11-10 16:00:00 EST

311.98

-8.41

-2.62%

盘后311.99

+0.01+0.00%

19:40 EST

最高323.73	最低307.08	成交量175.12万
今开318.65	昨收320.39	日振幅5.20%
总市值452.39亿	流通市值439.89亿	总股本1.45亿
成交额5.52亿	换手率1.24%	流通股本1.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NTRA","market":"US","secType":"STK","nameCN":"Natera, Inc.","latestPrice":311.98,"timestamp":1794344400000,"preClose":320.39,"halted":0,"volume":1751245,"hourTrading":{"tag":"盘后","latestPrice":311.99,"preClose":311.98,"latestTime":"19:40 EST","volume":31959,"amount":9970501.007,"timestamp":1794357608910,"change":0.01,"changeRate":0.000032,"amplitude":0.000032},"delay":0,"changeRate":-0.02624925871593985,"floatShares":141000000,"shares":145004521,"eps":-1.161556,"marketStatus":"未开盘","change":-8.41,"latestTime":"11-10 16:00:00 EST","open":318.65,"high":323.73,"low":307.08,"amount":551709895.64415,"amplitude":0.051968,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.161556,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1794387600000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1435809600000,"exchange":"NASDAQ","adjPreClose":320.39,"preHourTrading":{"tag":"盘前","latestPrice":318.34,"preClose":320.39,"latestTime":"09:29 EST","volume":364450,"amount":116765574.24700001,"timestamp":1794320999910,"change":-2.05,"changeRate":-0.006398,"amplitude":0.060736},"postHourTrading":{"tag":"盘后","latestPrice":311.99,"preClose":311.98,"latestTime":"19:40 EST","volume":31959,"amount":9970501.007,"timestamp":1794357608910,"change":0.01,"changeRate":0.000032,"amplitude":0.000032},"volumeRatio":0.473863,"impliedVol":0.5072,"impliedVolPercentile":0.5139},"requestUrl":"/m/hq/s/NTRA/tweets","defaultTab":"tweets","newsList":[{"id":"1118206919","title":"异动解读｜Natera盘中下跌13.9%，财报后盈利不及预期持续压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1118206919","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118206919?lang=zh_cn&edition=full","pubTime":"2026-11-06 22:45","pubTimestamp":1793976301,"startTime":"0","endTime":"0","summary":"11月6日，Natera盘中下跌13.9%，报321.2美元，成交额1.69亿美元。消息面上，公司最新披露的第三季度业绩呈现营收大幅超预期、但盈利端不及预期的分化表现，成为股价承压的直接因素。具体看，公司第三季度每股亏损0.42美元，差于市场预期的亏损0.28至0.29美元；同期营收7.94亿美元，高于市场预期约7.05亿至7.08亿美元，同比增长明显。公司同时将全年营收指引上调至30.05亿至30.35亿美元，但短线市场更聚焦盈利端逊于预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"财报后盈利不及预期，Natera盘中下跌","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114517950","title":"异动解读｜Natera盘前下跌16.16%，财报后盈利不及预期压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1114517950","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114517950?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:07","pubTimestamp":1793956021,"startTime":"0","endTime":"0","summary":"11月6日，Natera盘前下跌16.16%，报309.0美元，成交额7.1万美元。消息面上，公司最新披露的第三季度业绩呈现营收大幅超预期、但盈利端不及预期的分化表现，成为股价承压的直接触发因素。具体看，公司第三季度每股亏损0.42美元，差于市场预期的亏损0.28至0.29美元；同期营收7.94亿美元，明显高于市场预期约7.05亿至7.08亿美元，同比增长较快。公司同时将全年营收指引上调至30.05亿至30.35亿美元，高于此前29亿美元附近区间，但短线市场更聚焦盈利端逊于预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Natera财报盈利不及预期，盘前大跌","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108764588","title":"异动解读｜Natera夜盘下跌12.3%，财报后盈利不及预期压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1108764588","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108764588?lang=zh_cn&edition=full","pubTime":"2026-11-06 09:13","pubTimestamp":1793927588,"startTime":"0","endTime":"0","summary":"11月6日，Natera夜盘下跌12.3%，报319.0美元。消息面上，公司最新披露的第三季度业绩呈现营收大幅超预期、但每股亏损高于市场预期的分化表现，成为股价承压的直接触发因素。具体看，Natera第三季度每股亏损0.42美元，差于市场预期的亏损0.28至0.29美元；同期营收7.94亿美元，高于市场预期约7.05亿至7.08亿美元，同比增长明显。公司同时将全年营收指引上调至30.05亿至30.35亿美元，高于此前30亿以下区间，显示基本面增长仍强，但短线市场更聚焦盈利端不及预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"财报盈利不及预期，Natera夜盘跳水","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110654483","title":"异动解读｜Natera盘后下跌3.78%，短线缺乏新增催化下股价回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1110654483","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110654483?lang=zh_cn&edition=full","pubTime":"2026-11-06 05:07","pubTimestamp":1793912822,"startTime":"0","endTime":"0","summary":"11月6日，Natera盘后下跌3.78%，报350.0美元，成交额3528.07万美元。消息面上，公司近期公开信息整体仍偏利多，但与本次回落直接对应的新增负面催化并不明确，股价更像是在前期上涨后出现阶段性回吐。此前公司多癌早筛检测获FDA突破性医疗器械认定，Signatera在皮肤癌、乳腺癌及日本膀胱癌伴随诊断方向持续推进，且Roth Capital启动覆盖给予475美元目标价、Morgan Stanley上调目标价至435美元；但上述利多已被市场反复交易，对本次盘后下跌的直接解释力度有限。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera盘后走低，短线缺乏新增催化下股价回吐","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183785947","title":"异动解读｜Natera盘中下跌4.1%，短线缺乏新增催化下股价回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1183785947","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183785947?lang=zh_cn&edition=full","pubTime":"2026-11-05 22:30","pubTimestamp":1793889051,"startTime":"0","endTime":"0","summary":"11月5日，Natera盘中下跌4.1%，报372.34美元，成交额647.24万美元。消息面上，公司近期公开信息整体仍偏利多，但与本次回落直接对应的新增负面催化并不明确，股价更像是在前期上涨后出现阶段性回吐。此前公司已获多项积极进展，包括多癌早筛检测获FDA突破性医疗器械认定，Signatera在皮肤癌、乳腺癌及日本膀胱癌伴随诊断方向持续推进，叠加机构此前启动覆盖及上调目标价，强化了其中长期增长预期；但这些利多已被市场反复交易，对本次下跌的直接解释力度有限。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera盘中下跌，利多兑现后回吐","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119388452","title":"异动解读｜Natera盘前下跌3.38%，短线缺乏新增催化下股价回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1119388452","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119388452?lang=zh_cn&edition=full","pubTime":"2026-11-05 22:28","pubTimestamp":1793888923,"startTime":"0","endTime":"0","summary":"11月5日，Natera盘前下跌3.38%，报378.0美元，成交额31.51万美元。消息面上，公司近期公开信息整体仍偏利多，但与本次回落直接对应的新增负面催化并不明确，股价更像是在前期上涨后出现阶段性回吐。此前公司已获多项积极进展，包括Roth Capital启动覆盖并给予买入评级及475美元目标价、Morgan Stanley将目标价上调至435美元，以及多癌早筛检测获FDA突破性医疗器械认定；同时，Signatera在皮肤癌、乳腺癌及日本膀胱癌伴随诊断方向的推进，也持续强化其中长期增长预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera盘前下跌，短线回吐压力显现","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161492001","title":"异动解读｜Natera盘中下跌3.01%，短线缺乏新增催化下股价回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1161492001","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161492001?lang=zh_cn&edition=full","pubTime":"2026-11-04 23:33","pubTimestamp":1793806412,"startTime":"0","endTime":"0","summary":"11月4日，Natera盘中下跌3.01%，报373.645美元，成交额2.2亿美元。消息面上，公司近期公开信息整体仍偏利多，但与本次回落直接对应的新增负面催化并不明确，股价更像是在前期上涨后出现阶段性回吐。此前公司获得多项积极进展，包括Roth Capital启动覆盖并给予买入评级及475美元目标价、Morgan Stanley将目标价上调至435美元，以及多癌早筛检测获FDA突破性医疗器械认定，叠加Signatera在皮肤癌、乳腺癌及日本膀胱癌伴随诊断方向的推进，持续强化其中长期增长预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Natera盘中下跌，短线缺乏新增催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119841102","title":"异动解读｜Natera盘前上涨3.4%，资金再度聚焦既有利多","url":"https://stock-news.laohu8.com/highlight/detail?id=1119841102","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119841102?lang=zh_cn&edition=full","pubTime":"2026-11-04 18:26","pubTimestamp":1793788017,"startTime":"0","endTime":"0","summary":"11月4日，Natera盘前上涨3.4%，报395.0美元，成交额18.95万美元。消息面上，公司近期公开信息整体仍偏利多，本次上行更像是短线回吐后，资金重新交易前期已持续发酵的积极催化。具体看，Roth Capital此前启动覆盖并给予买入评级及475美元目标价，Morgan Stanley将目标价上调至435美元；同时，公司多癌早筛检测获FDA突破性医疗器械认定，Signatera在皮肤癌和乳腺癌方向的临床推进，以及日本膀胱癌伴随诊断审批进展，均强化了市场对其中长期增长空间的预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Natera盘前上涨，多重利好催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121948589","title":"异动解读｜Natera盘中上涨3.45%，短线回吐后资金再度聚焦既有利多","url":"https://stock-news.laohu8.com/highlight/detail?id=1121948589","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121948589?lang=zh_cn&edition=full","pubTime":"2026-11-03 22:38","pubTimestamp":1793716697,"startTime":"0","endTime":"0","summary":"11月3日，Natera盘中上涨3.45%，报394.57美元，成交额3.48亿美元。消息面上，公司近期公开信息整体偏利多，股价反弹主要仍围绕前期持续发酵的积极催化。其中，Roth Capital启动覆盖并给予买入评级及475美元目标价，Morgan Stanley将目标价上调至435美元；同时，公司多癌早筛检测获得FDA突破性医疗器械认定，叠加Signatera相关临床推进与海外审批进展，强化了市场对其中长期增长空间的预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Natera盘中上涨，机构密集上调目标价","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154447109","title":"异动解读｜Natera盘中下跌3.47%，短线缺乏新增催化下股价回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1154447109","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154447109?lang=zh_cn&edition=full","pubTime":"2026-11-02 23:06","pubTimestamp":1793632019,"startTime":"0","endTime":"0","summary":"11月2日，Natera盘中下跌3.47%，报399.915美元，成交额8881.95万美元。消息面上，公司近期公开信息整体仍偏利多，但暂无与本次盘中回落直接对应的新负面事件，异动更像是前期利好兑现后的回吐。此前公司获得多项积极催化，包括Roth Capital启动覆盖并给予买入评级及475美元目标价、Morgan Stanley将目标价上调至435美元，以及多癌早筛检测获FDA突破性医疗器械认定；不过这些利好已被市场持续消化，对本次下跌解释力度有限。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Natera利好兑现回落，短线缺乏新增催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143235528","title":"异动解读｜Natera盘中下跌3.27%，短线缺乏新增催化下股价回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1143235528","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143235528?lang=zh_cn&edition=full","pubTime":"2026-10-30 22:04","pubTimestamp":1793369048,"startTime":"0","endTime":"0","summary":"10月30日，Natera盘中下跌3.27%，报424.48美元，成交额8097.79万美元。整体而言，近期公开信息偏利多，尚无与本次盘中回落直接对应的新负面事件，当前异动更像是在既有利好兑现后的回吐，现有消息对本次下跌解释力度有限。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Natera盘中下跌，利好兑现后回吐","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166533379","title":"异动解读｜Natera盘前下跌3.67%，短线缺乏新增催化下股价回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1166533379","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166533379?lang=zh_cn&edition=full","pubTime":"2026-10-30 21:10","pubTimestamp":1793365859,"startTime":"0","endTime":"0","summary":"10月30日，Natera盘前下跌3.67%，报425.11美元，成交额77.39万美元。公开消息面看，公司近期最新明确催化仍是10月23日Roth Capital启动覆盖并给予买入评级及475美元目标价，高于当时市场平均目标价387.52美元；此前Morgan Stanley于10月12日将目标价上调至435美元，公司10月9日还披露多癌早筛检测获FDA突破性医疗器械认定。整体而言，近期公开信息偏利多，尚无与本次盘前回落直接对应的新负面事件，当前异动与既有利好消息解释力度有限。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Natera盘前下跌，短线缺乏催化下回吐","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166929651","title":"异动解读｜Natera盘中上涨3.01%，券商新覆盖并给出475美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1166929651","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166929651?lang=zh_cn&edition=full","pubTime":"2026-10-28 21:54","pubTimestamp":1793195682,"startTime":"0","endTime":"0","summary":"10月28日，Natera盘中上涨3.01%，报423.1901美元，成交额4583.07万美元。较新的消息面上，Roth Capital于10月23日启动覆盖Natera，给予买入评级和475美元目标价，高于公司当时约387.52美元的市场平均目标价，强化了市场对其估值上修预期。此前多家机构亦连续上调目标价，Morgan Stanley于10月12日将目标价升至435美元；公司10月9日还披露其多癌早筛检测获FDA突破性医疗器械认定，叠加Signatera相关临床与商业进展，构成股价近期走强的背景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Natera获券商买入评级，股价盘中上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108775004","title":"异动解读｜Natera盘中下跌3.25%，目标价上调后短线回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1108775004","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108775004?lang=zh_cn&edition=full","pubTime":"2026-10-22 22:17","pubTimestamp":1792678620,"startTime":"0","endTime":"0","summary":"10月22日，Natera盘中下跌3.25%，报399.94美元/股，成交额7625.1万美元。近期公司股价连续受投行上调目标价与产品进展催化走强，最新异动更像是此前上涨后的阶段性回吐。基本面上，公司上季度营收7.53亿美元，同比增长37.7%，并将全年营收指引上调至28.5亿至29.1亿美元，显示商业化推进与业绩兑现仍在强化中。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Natera盘中下跌，利好兑现后回吐","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134003322","title":"异动解读｜Natera盘中上涨3.13%，目标价上调叠加产品进展强化估值预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1134003322","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134003322?lang=zh_cn&edition=full","pubTime":"2026-10-21 21:53","pubTimestamp":1792590783,"startTime":"0","endTime":"0","summary":"10月21日，Natera盘中上涨3.13%，报418.615美元/股，成交额5222.68万美元。本次异动的直接催化，来自投行近期上调目标价并维持增持立场，叠加公司在多癌早筛与Signatera商业化上的连续进展，带动资金回流基因检测主线。此前摩根士丹利将其目标价由355美元上调至435美元；公司多癌早筛检测亦获FDA突破性设备认定，Signatera已在日本获批用于肌层浸润性膀胱癌伴随诊断。基本面方面，公司二季度营收7.53亿美元，同比增长37.7%，并将全年营收指引上调至28.5亿至29.1亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Natera获大行上调目标价，股价盘中上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174400496","title":"异动解读｜Natera盘中上涨3.03%，投行上调目标价后资金重回基因检测主线","url":"https://stock-news.laohu8.com/highlight/detail?id=1174400496","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174400496?lang=zh_cn&edition=full","pubTime":"2026-10-19 23:14","pubTimestamp":1792422849,"startTime":"0","endTime":"0","summary":"10月19日，Natera盘中上涨3.03%，报405.36美元/股，成交额1.17亿美元。消息面上，摩根士丹利近日将公司目标价由355美元上调至435美元，并维持增持评级，继续强化市场对其估值上修预期。同时，公司多癌早筛检测获FDA突破性设备认定，Signatera已在日本获批用于肌层浸润性膀胱癌伴随诊断，皮肤癌和乳腺癌相关临床项目也在推进。此前公司二季度营收7.53亿美元，同比增长37.7%，并上调全年营收指引至28.5亿至29.1亿美元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"股价上涨，基因检测龙头获投行力挺","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146436479","title":"异动解读｜Natera盘中下跌3.09%，投行上调目标价后短线回吐压力再现","url":"https://stock-news.laohu8.com/highlight/detail?id=1146436479","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146436479?lang=zh_cn&edition=full","pubTime":"2026-10-16 22:01","pubTimestamp":1792159268,"startTime":"0","endTime":"0","summary":"10月16日，Natera盘中下跌3.09%，报392.58美元/股，成交额4288.08万美元。消息面上，摩根士丹利近日将公司目标价由355美元上调至435美元并维持增持评级，但股价在前期强势后再度出现获利回吐。与此同时，公司多癌早筛检测获FDA突破性设备认定，Signatera已在日本获批用于肌层浸润性膀胱癌伴随诊断，皮肤癌和乳腺癌相关临床项目也在推进。不过生物科技板块承压，Moderna盘中跌超10%，短线情绪压制利好兑现。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera短线回吐，利好催化仍受关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168638777","title":"异动解读｜Natera盘中上涨3.15%，投行上调目标价后资金重回基因检测主线","url":"https://stock-news.laohu8.com/highlight/detail?id=1168638777","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168638777?lang=zh_cn&edition=full","pubTime":"2026-10-16 03:09","pubTimestamp":1792091347,"startTime":"0","endTime":"0","summary":"10月16日，Natera盘中上涨3.15%，报407.2美元/股，成交额3.19亿美元。消息面上，摩根士丹利近日将Natera目标价由355美元上调至435美元，并维持增持评级，叠加公司多癌早筛检测获FDA突破性设备认定，带动市场继续关注其长期增长前景。此外，Signatera此前已在日本获批用于肌层浸润性膀胱癌伴随诊断，公司近期还推进皮肤癌和乳腺癌相关临床项目。8月公司披露二季度营收7.53亿美元，同比增37.7%，并上调全年营收指引至28.5亿至29.1亿美元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Natera获大行上调目标价，股价上涨引资金回流","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106930041","title":"异动解读｜Natera盘中下跌3.24%，投行上调目标价不改获利回吐压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1106930041","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106930041?lang=zh_cn&edition=full","pubTime":"2026-10-13 21:52","pubTimestamp":1791899579,"startTime":"0","endTime":"0","summary":"10月13日，Natera盘中下跌3.24%，报384.89美元/股，成交额3740.92万美元。消息面上，摩根士丹利近日将Natera目标价从355美元上调至435美元，并维持增持评级，但股价在前期连续走强后仍出现回吐。公司近期基本面催化持续，包括多癌早筛检测获得FDA突破性设备认定、Signatera在日本获批用于膀胱癌伴随诊断，且皮肤癌、乳腺癌等临床项目推进中。不过当前生物科技板块整体偏弱，Moderna同步下跌，短线情绪压制强于利好兑现。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera股价回落，大摩上调目标价","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190330401","title":"异动解读｜Natera盘中下跌3.18%，投行上调目标价不改获利回吐压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1190330401","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190330401?lang=zh_cn&edition=full","pubTime":"2026-10-13 00:57","pubTimestamp":1791824236,"startTime":"0","endTime":"0","summary":"10月13日，Natera盘中下跌3.18%，报387.98美元/股，成交额1.46亿美元。消息面上，摩根士丹利将Natera目标价从355美元上调至435美元并维持增持评级，但股价在近期连续上涨后出现获利回吐。近期Natera在多癌早期检测领域取得进展，其多癌筛查检测获FDA突破性设备认定，Signatera测试也在日本获批用于膀胱癌伴随诊断，公司临床管线持续扩张。尽管投行目标价上调反映对长期基本面的看好，但短期内市场情绪受生物科技板块整体走弱影响，Moderna下跌4.58%，行业回调压力明显。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera盘中走低，投行却上调目标价","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.natera.com","stockEarnings":[{"period":"1week","weight":-0.1545},{"period":"1month","weight":-0.2004},{"period":"3month","weight":0.0245},{"period":"6month","weight":0.6403},{"period":"1year","weight":0.6054},{"period":"ytd","weight":0.3985}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0332},{"period":"3month","weight":-0.0232},{"period":"6month","weight":0.014},{"period":"1year","weight":0.1218},{"period":"ytd","weight":0.1038}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Natera, Inc.于2007年1月在特拉华州成立。该公司是一家诊断公司，拥有专有的分子和生物信息技术，该公司正在应用该技术来改变全球范围内的疾病管理。该公司的无细胞DNA（CFDNA）技术结合了新颖的分子分析方法，这些方法可以从小到单个细胞的样本中可靠地测量整个基因组中的许多信息区域，以及统计算法，这些算法结合了更广泛的科学界提供的数据，以高精度和高覆盖率识别涵盖广泛严重疾病的遗传变异。该公司的目标是使个性化基因检测和诊断成为保护健康的护理标准的一部分，并告知更早和更有针对性的干预措施，以帮助实现更长寿、更健康的生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":-0.017867},{"month":2,"riseRate":0.545455,"avgChangeRate":0.019142},{"month":3,"riseRate":0.454545,"avgChangeRate":0.002026},{"month":4,"riseRate":0.727273,"avgChangeRate":0.035796},{"month":5,"riseRate":0.818182,"avgChangeRate":0.097296},{"month":6,"riseRate":0.818182,"avgChangeRate":0.127144},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.000068},{"month":8,"riseRate":0.833333,"avgChangeRate":0.157241},{"month":9,"riseRate":0.416667,"avgChangeRate":-0.021704},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.034855},{"month":11,"riseRate":0.5,"avgChangeRate":0.073227},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.000753}],"exchange":"NASDAQ","name":"Natera, Inc.","nameEN":"Natera"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Natera, Inc.(NTRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Natera, Inc.(NTRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Natera, Inc.,NTRA,Natera, Inc.股票,Natera, Inc.股票老虎,Natera, Inc.股票老虎国际,Natera, Inc.行情,Natera, Inc.股票行情,Natera, Inc.股价,Natera, Inc.股市,Natera, Inc.股票价格,Natera, Inc.股票交易,Natera, Inc.股票购买,Natera, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Natera, Inc.(NTRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Natera, Inc.(NTRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}